Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Gotham Asset Management LLC

Gotham Asset Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,351 shares of the medical research company's stock after purchasing an additional 5,944 shares during the quarter. Gotham Asset Management LLC's holdings in Thermo Fisher Scientific were worth $15,269,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Full Sail Capital LLC raised its position in Thermo Fisher Scientific by 1.7% in the fourth quarter. Full Sail Capital LLC now owns 2,169 shares of the medical research company's stock worth $1,128,000 after acquiring an additional 37 shares in the last quarter. Ellevest Inc. raised its position in Thermo Fisher Scientific by 5.4% in the fourth quarter. Ellevest Inc. now owns 1,357 shares of the medical research company's stock worth $706,000 after acquiring an additional 70 shares in the last quarter. Ethic Inc. raised its position in Thermo Fisher Scientific by 13.7% in the fourth quarter. Ethic Inc. now owns 42,002 shares of the medical research company's stock worth $21,851,000 after acquiring an additional 5,066 shares in the last quarter. Farallon Capital Management LLC raised its position in Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after acquiring an additional 523,800 shares in the last quarter. Finally, First Manhattan CO. LLC. raised its position in Thermo Fisher Scientific by 0.6% in the fourth quarter. First Manhattan CO. LLC. now owns 891,321 shares of the medical research company's stock worth $464,010,000 after acquiring an additional 4,991 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

TMO has been the subject of several research analyst reports. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Scotiabank lowered their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Trading Down 5.0%

TMO traded down $21.57 during midday trading on Wednesday, hitting $407.38. The company's stock had a trading volume of 3,196,742 shares, compared to its average volume of 1,822,993. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market cap of $153.78 billion, a P/E ratio of 24.64, a PEG ratio of 2.99 and a beta of 0.82. The firm has a 50-day moving average price of $460.85 and a two-hundred day moving average price of $513.11. Thermo Fisher Scientific Inc. has a 52-week low of $401.75 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.11 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.